Published in J Immunol on December 10, 2012
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
Antibodies and tuberculosis. Tuberculosis (Edinb) (2016) 0.90
Striking a balance: fungal commensalism versus pathogenesis. Curr Opin Microbiol (2013) 0.86
Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. MBio (2015) 0.85
Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody. MBio (2016) 0.82
Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis. Fungal Genet Biol (2013) 0.79
Temporal behavior of capsule enlargement by Cryptococcus neoformans. Eukaryot Cell (2013) 0.77
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools. Front Microbiol (2015) 0.75
A Flagellar Glycan-Specific Protein Encoded by Campylobacter Phages Inhibits Host Cell Growth. Viruses (2015) 0.75
Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2005) 5.46
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis (1972) 3.75
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J Cell Sci (2002) 2.54
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis (1988) 2.03
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Information processing during phagocytosis. Nat Rev Immunol (2012) 1.84
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol (2004) 1.66
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Flexibility of human IgG subclasses. J Immunol (1997) 1.56
Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol (1989) 1.55
Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol (1998) 1.45
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol (2001) 1.42
IgG3 is the major source of cryoglobulins in mice. J Immunol (1989) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. J Clin Microbiol (2012) 1.30
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
A new synthesis for antibody-mediated immunity. Nat Immunol (2011) 1.24
Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today (1992) 1.22
Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 1.20
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16
A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis (1998) 1.15
Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun (1998) 1.14
Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule. Eukaryot Cell (2009) 1.08
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe (2012) 1.07
Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. MBio (2011) 1.03
Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans. J Immunol Methods (1995) 1.01
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother (1995) 1.00
Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol (2005) 1.00
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun (2004) 0.98
Isolation and characterization of senescent Cryptococcus neoformans and implications for phenotypic switching and pathogenesis in chronic cryptococcosis. Eukaryot Cell (2009) 0.94
The elastic properties of the Cryptococcus neoformans capsule. Biophys J (2009) 0.94
Coping with multiple virulence factors: which is most important? PLoS Pathog (2005) 0.93
Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells. PLoS One (2012) 0.90
Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans. Infect Immun (2011) 0.87
Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation. Cell Microbiol (2008) 0.86
Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Clin Exp Immunol (1996) 0.85
Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding. Fungal Genet Biol (2012) 0.82
Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates. J Clin Microbiol (1999) 0.80
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Retracted science and the retraction index. Infect Immun (2011) 3.35
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci (2003) 1.40
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Vesicular transport across the fungal cell wall. Trends Microbiol (2009) 1.36
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol (2008) 1.36
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun (2009) 1.36
The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell Melanoma Res (2008) 1.36
Reforming science: structural reforms. Infect Immun (2011) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 1.32
Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun (2002) 1.31
Vesicle-associated melanization in Cryptococcus neoformans. Microbiology (2009) 1.31
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30